Pharmacological inhibition of LCK reverses GC resistance in PPR T-ALL cells. (A) ALL-SIL cells were treated at the molar ratio (drug: Dex) of 0.1:1 for dasatinib, 0.1:1 for bosutinib, 10:1 for nintedanib, and 10:1 for WH-4-023. (B) CCRF-CEM cells were treated at the molar ratio (drug: Dex) of 30:1 for dasatinib, 100:1 for bosutinib, 10:1 for nintedanib, and 10:1 for WH-4-023. (C) TALL-1 cells were treated at the molar ratio (drug: Dex) of 100:1 for dasatinib, 50:1 for bosutinib, 100:1 for nintedanib, and 100:1 for WH-4-023. Cell viability was determined by MTT test after 48 hr of treatment (n = at least 3 for all experiments). Results are presented as means ± SEM.